News

A new validated risk model identifies advanced cancer trial patients at highest risk for acute care use

Adding ruxolitinib to TKI treatment for chronic-phase chronic myeloid leukemia (CML) increases deep molecular response rate

Tumors with alterations in any of three specific DNA damage-repair genes were more likely than other tumors to be eliminated by cisplatin-based chemotherapy.

Pilot confirms acceptability of bowel symptom intervention for survivors of rectal cancer

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL

Ten years on, Lung-MAP success demonstrates potential of public-private partnerships in clinical research